Human leukocyte antigen class I histocompatibility antigen, A-24 alpha chain (HLA-A24)

HLA-A24 is a member of the human leukocyte antigen (HLA) class I family, encoded by the HLA-A*24 allele group. It is a highly polymorphic membrane glycoprotein composed of an α chain (encoded by the HLA-A gene) associated non-covalently with β2-microglobulin. HLA-A24’s primary function is to present endogenous peptide fragments (from proteins within the cytoplasm, such as viral or tumor antigens) to CD8+ cytotoxic T lymphocytes, initiating immune responses against infected or malignant cells. Its distribution varies widely among human populations and it plays a crucial role in immune surveillance, organ transplantation compatibility, and the pathogenesis of various autoimmune diseases and and cancers. Due to its immunological specificity, HLA-A24 is a key stratification and selection marker in immunotherapies, particularly peptide-based cancer vaccines and T cell therapies.

Other names

HLA-A*24HLA A24A24Human leukocyte antigen A24HLA class I histocompatibility antigen A-24

For peptide vaccines and immunotherapies: HLA-A24 displays synthetic or tumor-derived peptides to activate or expand cytotoxic T lymphocytes specific for cancer cells or infected cells. Cellular therapies: HLA-A24-restriction is critical for the selection of TCR-engineered T cells and adoptive therapy candidates.